Want to see CANF full AI Analyst Report?
Top Page
Can-Fite BioPharma
(CANF)
Select Model
Select Model
Rating:39Underperform
Price Target:
$3.50
▲(9.72% Upside)
Action:Downgraded
Date:03/28/26
Low score driven by poor financial trajectory (declining revenue, rising losses, cash burn) and bearish technicals (price far below DMAs, sell signals); low debt offers minor buffer but execution risks dominate in biotech.
Positive Factors
Platform breadth
Independent, peer-reviewed validation that A3AR activation affects multiple disease pathways strengthens Can‑Fite’s platform optionality. A broadly applicable mechanism supports multiple development programs, expands licensing and partnership opportunities, and reduces reliance on any single indication over the next 2–6 months and beyond.
Negative Factors
Declining revenue & losses
Sustained small and falling revenues alongside persistent operating and net losses indicate weak commercial traction and an inability to self‑fund operations. Over months this erodes financial flexibility, forces continued reliance on external capital, and increases execution risk for late‑stage trials and commercialization plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform breadth
Independent, peer-reviewed validation that A3AR activation affects multiple disease pathways strengthens Can‑Fite’s platform optionality. A broadly applicable mechanism supports multiple development programs, expands licensing and partnership opportunities, and reduces reliance on any single indication over the next 2–6 months and beyond.
Read all positive factors
Can-Fite BioPharma (CANF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.22M
Dividend YieldN/A
Average Volume (3M)258.05K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.70
Shares Outstanding2,142,546
10 Day Avg. Volume432,468
30 Day Avg. Volume258,053
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.07
P/FCF Ratio-0.37
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$7.50Price Target Upside135.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Can-Fite BioPharma Business Overview & Revenue Model
Company Description
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders...
How the Company Makes Money
null...
Can-Fite BioPharma Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
65
Positive
Cash Flow
35
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 408.21K | 674.00K | 743.00K | 810.00K | 853.00K |
| Gross Profit | 384.02K | 674.00K | 743.00K | 810.00K | 853.00K |
| EBITDA | -10.00M | -8.12M | -8.18M | -10.08M | -12.83M |
| Net Income | -9.91M | -7.88M | -7.63M | -10.17M | -12.60M |
Balance Sheet | |||||
| Total Assets | 9.51M | 9.12M | 9.99M | 9.28M | 20.25M |
| Cash, Cash Equivalents and Short-Term Investments | 8.54M | 7.89M | 8.92M | 7.98M | 19.14M |
| Total Debt | 71.00K | 104.00K | 40.00K | 62.00K | 124.00K |
| Total Liabilities | 3.92M | 3.68M | 3.75M | 4.81M | 5.87M |
| Stockholders Equity | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
Cash Flow | |||||
| Free Cash Flow | -9.02M | -7.64M | -8.44M | -10.81M | -9.87M |
| Operating Cash Flow | -9.02M | -7.64M | -8.44M | -10.80M | -9.86M |
| Investing Cash Flow | -2.02K | 1.50M | 498.00K | 9.50M | -14.51M |
| Financing Cash Flow | 9.72M | 6.71M | 9.14M | 0.00 | 20.46M |
Can-Fite BioPharma Risk Analysis
Can-Fite BioPharma disclosed 68 risk factors in its most recent earnings report. Can-Fite BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
Can-Fite BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $5.95M | -0.20 | -281.30% | ― | ― | 86.07% | |
46 Neutral | $12.27M | -0.80 | -5456.14% | ― | -100.00% | 59.83% | |
42 Neutral | $2.17M | >-0.01 | -694.46% | ― | ― | -92.20% | |
39 Underperform | $7.22M | -0.73 | -201.06% | ― | ― | ― |
* Healthcare Sector Average
CANF
Can-Fite BioPharma
3.17
-10.32
-76.50%
GNPX
Genprex
4.75
-264.75
-98.24%
BCDA
BioCardia
0.83
-1.13
-57.60%
PCSA
Processa Pharmaceuticals
2.13
-3.65
-63.15%
PHGE
BiomX
0.19
-8.02
-97.73%
Can-Fite BioPharma Corporate Events
Can-Fite’s Namodenoson Pancreatic Cancer Data Accepted for ESMO 2026 Presentation
Jul 20, 2026
On July 20, 2026, Can-Fite BioPharma reported that positive Phase 2a data for its oral drug Namodenoson in advanced pancreatic ductal adenocarcinoma were accepted for poster presentation at the European Society for Medical Oncology Congress 2026. ...
Can-Fite BioPharma Wins Australian Patent Backing Namodenoson in Liver and Pancreatic Cancer
Jul 14, 2026
On July 14, 2026, Can-Fite BioPharma announced that the Australian Patent Office has allowed its patent application titled “Treatment of Advanced Metastatic Cancer,” strengthening intellectual property protection for its oncology drug ...
Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson
Jul 6, 2026
On July 6, 2026, Can-Fite BioPharma announced it has completed enrolment of the first 247 patients in its pivotal Phase 3 trial of Piclidenoson for moderate-to-severe plaque psoriasis, triggering a pre-specified interim analysis under a protocol a...
Can-Fite’s Namodenoson Hits Safety Goal and Shows Durable Survival in Phase 2a Pancreatic Cancer Trial
Jul 1, 2026
On July 1, 2026, Can-Fite BioPharma reported Phase 2a data for Namodenoson in advanced pancreatic ductal adenocarcinoma, showing the trial met its primary safety endpoint and was well tolerated across 20 heavily pretreated patients. The open-label...
Can-Fite BioPharma Wins Japanese Patent for Namodenoson’s Anti-Obesity Technology
Jun 26, 2026
On June 26, 2026, Can-Fite BioPharma announced that the Japan Patent Office has allowed a patent covering the use of A3 adenosine receptor agonists, including its lead candidate Namodenoson, for inducing fat loss and treating obesity and related m...
Can-Fite BioPharma Showcases Broad Potential of A3AR Drug Platform in New Peer-Reviewed Study
Jun 22, 2026
On June 22, 2026, Can-Fite BioPharma announced the publication of a peer-reviewed article in Biomolecules highlighting the broad therapeutic potential of its A3 adenosine receptor agonists, Piclidenoson and Namodenoson. The review compiles data fr...
Can-Fite BioPharma to Showcase Late-Stage Pipeline and Licensing Deals at BIO 2026
Jun 17, 2026
On June 17, 2026, Can-Fite BioPharma announced it will present its late-stage clinical pipeline and licensing opportunities at the BIO International Convention 2026, held June 22–25 in San Diego. The company plans extensive partnering meetin...
Can-Fite BioPharma Shareholders Approve All Proposals at 2026 Annual Meeting
Jun 4, 2026
On June 4, 2026, Can-Fite BioPharma Ltd. held its Annual General Meeting of Shareholders, where investors voted on five proposals presented by management. The company reported that all five proposals were approved by the required majorities, signa...
Can-Fite BioPharma Posts Positive Phase 2a Signal for Namodenoson in Pancreatic Cancer
Jun 2, 2026
On June 2, 2026, Can-Fite BioPharma reported encouraging clinical observations from its ongoing Phase 2a trial of namodenoson as a monotherapy in pancreatic cancer, where enrollment is complete and several patients have shown prolonged disease con...
Can-Fite BioPharma Adjourns 2026 Shareholder Meeting for Lack of Quorum
May 28, 2026
On May 28, 2026, Can-Fite BioPharma convened its 2026 Annual General Meeting of Shareholders in Ramat Gan, Israel, but the meeting was adjourned for one week due to a lack of quorum. The meeting is now scheduled to be reconvened on June 4, 2026, a...
Can-Fite and Vetbiolix Gain Peer-Reviewed Validation for Piclidenoson in Canine Osteoarthritis
May 18, 2026
On May 18, 2026, Can-Fite BioPharma and Vetbiolix reported that a peer-reviewed article in Frontiers in Veterinary Science described positive study results for Piclidenoson in dogs with osteoarthritis. The oral A3 adenosine receptor agonist signif...
Can-Fite to Advance Namodenoson into Phase 2b Pancreatic Cancer Combo Trial After Positive Data
May 13, 2026
On May 13, 2026, Can-Fite BioPharma announced that, following positive interim results from its ongoing Phase 2a trial in advanced pancreatic adenocarcinoma, it plans to advance its oral A3 adenosine receptor agonist Namodenoson into a Phase 2b st...
Can-Fite Posts Positive Phase 2a Results for Namodenoson in Advanced Pancreatic Cancer
Apr 30, 2026
On April 30, 2026, Can-Fite BioPharma reported positive Phase 2a data for its A3 adenosine receptor agonist namodenoson in advanced pancreatic cancer, showing preliminary clinical activity and durable disease stabilization in a heavily pretreated ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.